WO1999041985A1 - P53-dependent secretion of growth inhibitory factors - Google Patents
P53-dependent secretion of growth inhibitory factors Download PDFInfo
- Publication number
- WO1999041985A1 WO1999041985A1 PCT/US1999/003777 US9903777W WO9941985A1 WO 1999041985 A1 WO1999041985 A1 WO 1999041985A1 US 9903777 W US9903777 W US 9903777W WO 9941985 A1 WO9941985 A1 WO 9941985A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- growth inhibitory
- inhibitory factors
- dependent
- growth
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates generally to the p53-dependent secretion of growth inhibitory factors and more particularly to a method for preparing p53 -dependent growth inhibitory factors for use in a pharmaceutical composition and a method for reducing cell proliferation.
- the p53 tumor suppressor gene encodes a nuclear transcription factor (tumor suppressor protein) , that accumulates in the cells in response to a variety of stresses and that is a key component of a cellular mechanism of stress response (for review see Gott Kunststoff et al . , 1996) .
- This tumor suppressor protein which has rapid turnover, is stabilized in the cell under various stressful conditions including DNA damage (Maltzman et al . , 1984; Kastan et al . , 1991), deregulation of microtubules (Tishler et al . , 1995), hypoxia (Graeber et al . , 1996) and detachment from its natural substrate (Nikiforov et al . ) .
- Normal function of p53 is required for control of cell aging (Atadja et al . , 1995) .
- Cell response to certain growth factors also requires p53
- p53 The biological effects of p53 are cell type specific. For example, in vivo it determines massive apoptosis in response to gamma irradiation or treatment with chemotherapeutic drugs only in early embryos and several sensitive tissues, including spleen and thymus (Lowe et al . , 1993a; MacCallum et al . , 1996; Komarova et al . , 1997). Many p53 -mediated effects are achieved through the activity of p53- responsive genes.
- p53 Functional inactivation of p53 occurs in the majority of cancers and established cell lines (Vogelstein et al . , 1992) . It is achieved by mutations (many of which generate dominant negative variants of p53), deletions or inhibitory activity of p53 -interacting proteins of cellular (such as mdm-2) or viral (such as large SV40 T-antigen, E6 protein or papilloma virus, etc.) origin (see references cited in Gottling et al . , 1996) . Lack of p53 in normal cells leads to the loss of genomic stability (Yin et al . , 1992), spontaneous immortalization (Donehower et al .
- Loss of p53 by tumor cells may be associated with high resistance to chemo- and radiation therapy and the establishment of metastatic behavior through suppression of p53 -mediated programmed cell death (Nikiforov et al . ; Lowe et al . 1993a; Lowe et al . , 1993b and Thompson et al . , 1995) .
- p53 serves to control apoptosis elimination of genetically damaged cells in early stages of embroyogenesis (Norimura et al . , 1996 and Komarova et al . , 1997) . Lack of p53 in p53 knock-out mice leads to a high incidence of spontaneous cancers in adult animals (Donehower et al . , 1992; Jacks et al . , 1994) and to high frequency of teratogenic abnormalities in embryos exposed to ionizing radiation (Norimura et al . , 1996) .
- Anti-cancer therapy regimens involve a variety of stress- inducing treatments (radiation, chemotherapeutic drugs, hyperthermia, etc.) the toxicity of which is higher for cancer cells than for normal cells. Many of these treatments lead to the activation of p53 and subsequent p53 -dependent 5 growth arrest or apotosis (Gott Kunststoff et al . , 1996) .
- the conventional mode of thinking is that cell death occurs as a result of damage of intracellular components that trigger cell death, and the anti-cancer effect is believed to be associated either with stronger damage or with stronger apoptotic 0 response of malignant versus normal cells.
- anti-cancer therapy is usually damaging not only to the tumor but also to normal tissues, much effort has been made in targeting stress treatment specifically and selectively at cancer cells.
- anti- 5 cancer therapy with stress-inducing treatments is not limited to the internal damage occurring within cancer cells after therapeutic treatment.
- shielding the tumor in a tumor-bearing animal does not completely prevent it from exhibiting the anti-tumor effect of whole-body gamma 0 irradiation (Seung et al . , 1996) .
- p53 protein In response to treatment with radiation or hyperthermia, or with DNA-damaging or microtubule-targeted chemotherapeutic drugs, p53 protein accumulates in the cell (Gott Kunststoff et al . , 1996) .
- the tolerable doses of anticancer drugs and radiation are limited by their toxicity to several sensitive tissues, including hematopoietic organs, where transgenic animal studies showed that this effect is p53 dependent ( Komarova et al . , 1997) .
- the efficacies of chemo- and radiation therapies are mediated by p53, and at the same time, are limited by p53 -dependent toxicity for normal tissues .
- the present invention firstly provides a method for preparing a preparation of p53 -dependent growth inhibitory factors from a culture of normal human cells in a nutrient medium for use as antiproliferative agents, such as an anticancer therapeutic.
- the present invention further provides a pharmaceutical composition comprising a preparation of p53- dependent growth inhibitory factors prepared from a culture of human cells induced to express and secrete p53 -dependent growth inhibitory factors .
- Also provided by the present invention is a method for reducing unwanted or abnormal cell proliferation by administering a pharmaceutical composition containing a preparation of p53 -dependent growth inhibitory factors.
- Another object provided by the present invention is a method for preventing or delaying cell senescence by administering a pharmaceutical composition containing an agent which attenuates the secretion of or neutralizes the growth suppressive effects of one or more p53 -dependent growth inhibitory factors .
- FIG. 1 shows a graph of the results of a tumor growth inhibition assay, which demonstrates tumor suppression in vivo by conditioned medium. Mice were examined weekly for tumor growth. Four weeks after injection, tumors developed in approximately half of the injected sites in the control group, while the experimental group of injected animal tumors appeared in only three of 20 sites injected. This result suggests that factors secreted by irradiated splenocytes possess in vivo detectable anticancer activity.
- Figures 2A and 2B show detection of p53 -responsive genes by differential hybridization with ATLAS cDNA Array (CLONTECH Laboratories, Inc., Palo Alto, CA) (Fig. 2A) and Northern blot hybridization (Fig. 2B) .
- FIG. 2A similar areas of nylon membranes hybridized with 32 P-labeled cDNA from three organs (liver, spleen, and thymus) of untreated and gamma- irradiated p53-null and wild type mice are shown. Radiation responses of three indicated serine protease inhibitors illustrate the tissue-specificity and p53- dependence of their expression.
- Fig. 2B The results of hybridization to cDNA arrays were confirmed by Northern blot hybridization for serine protease inhibitor 2 (Fig. 2B) .
- the abbreviations shown in Figs. 2A and 2B are as follows: 1 - ⁇ l-protease inhibitor 2; 2- serine protease inhibitor 2; 3- serine proteinase inhibitor 2.4; -wt- wild type; -/- -p53 knockout; u/t - untreated; and ⁇ - gamma irradiated.
- Figures 3A and 3B show different patterns of p53- dependent gene regulation as determined by Northern hybridization with RNA from cells that have been treated as indicated - untreated (u/t) MDAH041 cells gamma irradiated (y) MDAH041 cells, tetracycline added (+ tetr) TR9-7 cells, no tetracycline added (- tetr) cells and gamma irradiation + tetracycline added ( ⁇ + tetr) .
- FIG. 4A-4F show that growth inhibition of prostate tumor cells DU145 by conditioned media and urine depends on p53 activation and p53 induction (Figs. 4A-4C) and p53 induction by Western immunoblotting (Figs. 4D-4F) .
- Bar diagrams (Figs. 4A-4C) show cell growth rate estimated as percent of 3 H-thymidine incorporation by the DU145 cells, growing in the presence of conditioned medium from untreated (left bar of bar pairs, considered as 100%) and gamma- irradiated (right bar of bar pairs) cells.
- Fig 4A mouse embryo fibroblasts (MEF) transformed with Ela + ras, p53-deficient (- /-), p53 wild type (wt) , transduced with either bcl-2 (bcl-2) or anti-p53 GSE (GSE) ;
- Fig. 4B Balb 3T3 cells, line ConA (wt) and their derivatives expressing anti-p53 GSE (GSE) ;
- Fig. 4C human skin fibroblasts MDAH041 (-/-) and TR9-7 (wt) .
- FIG. 4C corresponds to human fibroblasts (line TR9-7) with tetracycline-regulated wild type p53 activated by tetracycline deprivation.
- Figs. 4D-4F show the results of Western immunoblotting with MEF (Fig. 4D) and human fibroblasts (Fig. 4F) , demonstrating p53 induction after gamma irradiation, and X-gal staining of ConA cells (marked Balb 3T3) (Fig. 4E) .
- Figures 5A-5C shows the growth suppressive effect of conditioned media from short-term cultures of irradiated p53- null (p53 -/-) and wild type (wt) splenocytes (Fig. 5A) collected at the different time points indicated and urine (Fig. 5B) from p53-null and p53-wild type mice before (control) and after gamma irradiation (gamma) .
- Immunoperoxidase staining of irradiated p53-wild type and p53- null splenocytes from p53 is shown in the left bottom corner of Fig. 5A.
- Fig. 5B urine samples from six p53-wild type (crosses) and six p53-null mice (dots) harvested before and after irradiation were tested individually (Fig. 5B) .
- Fig. 5C shows a comparison of growth suppressive effect of different dilutions of conditioned medium from gamma irradiated ConA cells on different indicated target cells (NMuMG, HSF, and DU145) .
- Figures 6A-6D show adriamycin induced degradation of colonies of multidrug resistant KB/8-5-11 cells growing on p53-wild type (Figs. 6A and 6C) , but not on p53-null (Figs. 6B and 6D) , human fibroblasts.
- Representative microscopic view at lOx (Figs. 6A and 6B) and 40x (Figs. 6C and 6D) magnification of colonies of KB8-5-11 cells after 5 days of treatment with 50 ng/ml of adriamycin are shown.
- Figure 7 shows a graph of a comparison of adriamycin dependence on numbers of colonies formed by KB8-511 cells plated on wild type and p53 -deficient human fibroblast .
- the present invention is based on the discovery by the present inventors that the activation of p53 in normal noncancerous cells induces the expression and secretion of growth inhibitory factors possessing anti-cancer activity.
- the present inventors found an accumulation of radiation- induced factors, which cause antiproliferative effects on a variety of tumor cell lines, in the media from established and primary cell cultures and in vivo in the urine of mice after gamma irradiation in vi tro .
- p53- dependent factors released by normal cells potentiated the cytotoxic effect of chemotherapeutic drugs for co-cultivated tumor cells. Accordingly, p53 -dependent growth inhibitory factors secreted by normal cells play a role in the chemo- and radiation therapies for treating cancer.
- One aspect of the present invention is directed to a method for preparing a preparation of p53 -dependent growth inhibitory factors from cultured normal human cells by subjecting the cell culture to a stress treatment, i.e., gamma irradiation, to induce the expression and secretion of p53- dependent growth inhibitory factors.
- the p53 -dependent growth inhibitory factors secreted into the culture medium to form a conditioned medium is then recovered to prepare a preparation of p53 -dependent growth inhibitory factors for use in the second aspect of the invention, which is a pharmaceutical composition for reducing unwanted or abnormal cell proliferation .
- This method for preparing a preparation of p53-dependent growth inhibitory factors involves culturing human cells so that p53 tumor suppressor protein is expressed in response to a stress treatment (i.e., preferably gamma irradiation) , which p53 tumor suppressor protein acts to induce the expression and secretion of p53 -dependent growth inhibitory factors into the culture medium.
- the conditioned medium formed by the release of growth inhibitory factors into the nutrient culture medium is then processed to recover the p53-dependent growth inhibitory factors (i.e., TGF-beta 2, inhibin-beta, and serine protease inhibitors) and provide a preparation of such growth inhibitory factors.
- the human cells used in the method according to the present invention are preferably fibroblasts cells, spleen or thymus cells, and mixtures thereof.
- Other suitable cells for use in the present method can be readily identified by determining whether they express p53 in response to a stress treatment, the expression which of then induces the expression and secretion of one or more p53 -dependent growth inhibitory factors.
- p53 -dependent growth inhibitory factors expressed vary depending on cell type, a mixed culture of different cell types can be used to produce a preparation containing a broad spectrum of p53 -dependent growth inhibitory factors .
- Serum is an expensive commodity which is not readily available in amounts required for commercial production. It is also a biochemically undefined material. Serum is known to contain many major components including albumin and transferrin and also minor components, many of which have not been fully identified nor their action determined. Thus, serum will differ from batch to batch possibly requiring testing to determine levels of the various components and their effect on the cells.
- BSE Bovine Spongiform Encephalopathy
- the culture medium used for producing a preparation of p53-dependent growth inhibitory factors be serum-free.
- serum-free media with or without specific substitutes for components/factors in serum, is a defined media from which a preparation of p53 -dependent growth inhibitory factor can be purified.
- examples of such serum-free media suitable for human cells are the commonly used DMEM and RPMI media are well known.
- Many other serum- free media with or without substitutes for serum component are also well known in the art with some being commercially available from suppliers such as Life Technologies, Gaithersburg, MD.
- Those of skill in the art are furthermore quite capable of optimizing the defined components of a serum-free media for the growth of the cell type(s) to be used in the method according to the present invention.
- the serum- free media is preferably a defined media
- all the components of the media are known. Therefore, one of skill in the art is quite capable of developing with only routine experimentation a purification scheme for removing media components to prepare a preparation of p53- dependent growth inhibitory factors suitable for administering to a subject in a pharmaceutical composition.
- repeated cycles of ultrafiltration and washes may sufficiently remove the media components that little or no further purification procedures are needed to prepare the preparation of p53 -dependent growth inhibitory factors .
- the preparation of p53 -dependent growth inhibitory factors prepared according to the method of the present invention can be formulated into a pharmaceutical composition for use in reducing unwanted or abnormal cell proliferation.
- An effective amount of the pharmaceutical composition is administered to a subject in need thereof, such as a cancer patient, in a method for reducing cell proliferation where the proliferation of cells is unwanted or abnormal, i.e., neoplasms and malignant cancer cells.
- the method for reducing unwanted or abnormal cell proliferation may involve the administration of the pharmaceutical composition containing a preparation of p53 -dependent growth inhibitory factors as the sole treatment, it may be preferable and advantageous to combine this administration with conventional chemotherapy and/or radiation therapy to potentiate the cytotoxic effects of chemotherapeutic drugs or enhance the antiproliferative effects of radiation therapy.
- the pharmaceutical composition of the present invention is administered and dosed in accordance with good medical practice, taking into account the clinical condition of the individual patient, the site and method of administration, scheduling of administration, patient age, sex, body weight and other factors known to medical practitioners.
- the pharmaceutically "effective amount" for purposes herein is thus determined by such considerations as are known in the art. The amount must be effective to achieve improvement including but not limited to improved survival rate or more rapid recovery, or improvement or elimination of symptoms and other indicators as are selected as appropriate measures by those skilled in the art.
- the compound of the present invention can be administered in various ways.
- the preparation of p53 -dependent growth inhibitory factors can be administered alone as the pharmaceutical composition or as active ingredients in combination with pharmaceutically acceptable carriers, diluents, excipients, adjuvants, vehicles and auxiliary agents.
- the pharmaceutical composition can be administered orally, subcutaneously or parenterally including intravenous, intraarterial, intramuscular, intraperitoneally, and intranasal administration as well as intrathecal and infusion techniques. Implants containing the preparation are also useful.
- the pharmaceutically acceptable carriers, diluents, adjuvants and vehicles as well as implant carriers generally refer to inert, non-toxic solid or liquid fillers, diluents or encapsulating material not reacting with the active ingredients of the invention.
- the doses may be single doses or multiple doses over a period of several days, but single doses are preferred.
- compositions of the present invention When administering the pharmaceutical composition of the present invention parenterally, it will generally be formulated in a unit dosage injectable form (solution, suspension, emulsion) .
- the pharmaceutical formulations suitable for injection include sterile aqueous solutions or dispersions and sterile powders for reconstitution into sterile injectable solutions or dispersions.
- the carrier can be a solvent or dispersing medium containing, for example,
- Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- Nonaqueous vehicles such as cottonseed oil, sesame oil, olive oil, soybean oil, corn oil, sunflower oil, or peanut oil and esters, such as isopropyl myristate, may also be used as solvent systems for compound compositions.
- various additives which enhance the stability, sterility, and isotonicity of the compositions including antimicrobial preservatives, antioxidants, chelating agents, and buffers, can be added.
- antibacterial and antifungal agents for example, parabens, chlorobutanol , phenol, sorbic acid, and the like.
- isotonic agents for example, sugars, sodium chloride, and the like.
- Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, to the present invention, however, any vehicle, diluent, or additive used would have to be compatible with the compounds.
- Sterile injectable solutions can be prepared by incorporating the preparation of p53 -dependent growth inhibitory factors utilized in practicing the present invention in the required amount of the appropriate solvent with various of the other ingredients, as desired.
- a pharmacological formulation of the present invention can be administered to the patient in an injectable formulation containing any compatible carrier, such as various vehicle, adjuvants, additives, and diluents; or the compounds utilized in the present invention can be administered parenterally to the patient in the form of slow-release subcutaneous implants or targeted delivery systems such as monoclonal antibodies, vectored delivery, iontophoretic, polymer matrices, liposomes, and microspheres . Examples of
- -12- delivery systems useful in the present invention include: 5,225,182; 5,169,383; 5,167,616; 4,959,217; 4,925,678; 4,487,603; 4,486,194; 4,447,233; 4,447,224; 4,439,196; and 4,475,196.
- Many other such implants, delivery systems, and modules are well known to those skilled in the art.
- a pharmacological formulation of the compound utilized in the present invention can be administered orally to the patient .
- Conventional methods such as administering the compounds in tablets, suspensions, solutions, emulsions, capsules, powders, syrups and the like are usable.
- Known techniques which deliver it orally or intravenously and retain the biological activity are preferred.
- the pharmaceutical composition of the present invention can be administered initially by intravenous injection to bring blood levels to a suitable level.
- the patient's levels are then maintained by an oral dosage form, although other forms of administration, dependent upon the patient's condition and as indicated above, can be used.
- the quantity to be administered will vary for the patient being treated and will vary from about 100 ng/kg of body weight to mg/kg of body weight per day and preferably will be from 10 ⁇ g/kg to 10 mg/kg per day.
- the laboratory of the present inventors have also discovered that the onset of senescence in rat and chicken embryo fibroblasts is associated with the accumulation of growth inhibitory factors in conditioned medium.
- Culture media conditioned by senescent rat embryo fibroblasts (REFs) was growth suppressive to a broad variety of target cells including young REFs and a series of tumor cell lines.
- the growth suppressive effect was neutralized after 1 hr. incubation of conditioned media at 56°C.
- •13- invention is directed to a method for preventing or delaying cell senescence, which involves administering to a subject in need thereof a pharmaceutical composition containing an agent which has the activity of directly or indirectly attenuating the secretion of or neutralizing the growth suppressive effects of p53 -dependent growth inhibitory factors released by gradually accumulating senescent cells.
- the features of formulating the agent in a pharmaceutical composition, dosage and how it is administered, as discussed above with the pharmaceutical composition containing a preparation of p53- dependent growth inhibitory factors also apply to a pharmaceutical composition containing this agent for attenuating the secretion of or neutralizing the growth suppressive effects of p53 -dependent growth inhibitory factors .
- p53 can act as a tumor suppressor by inhibiting growth of damaged cells through internal control of cell cycle and apoptotic machinery and that the activation of p53 in normal cells induces the production and release of growth inhibitory factors possessing anti proliferative/anti-cancer activity.
- the growth inhibitory effect of conditioned media from the cells differing in their p53 status before and after p53 activation was compared.
- Three experimental cell systems, representing pairs of isogenic cell lines differing in their p 53 status or activity, were specifically designed to analyze p53 function as follows:
- TR9-7 under the control of tetracycline-inducible promoter (Agarwal et al . , 1995) .
- the level of p53 expression in TR9-7 in the presence of tetracycline is comparable to that of normal p53 -containing fibroblasts.
- p53 activation (stabilization) in TR9-7 was achieved either by gamma irradiation in the presence of tetracycline or by deprivation of the antibiotic.
- This line was compared with its variant obtained by retroviral transduction with anti-p53 GSE-56 acting as a strong dominant negative inhibitor of p53 function (Ossovskaya et al . , 1996) .
- p53 activation was achieved by gamma irradiation.
- Mouse embryo fibroblasts (MEF) with wild type p53 transformed with a combination of Ela and transforming Haras (cell line C8) were compared with their derivatives transduced with retroviral vectors expressing either anti-p53 genetic suppressor element (GSE) C2 (analog of GSE-56) or bcl- 2 (Nikiforov et al . , 1997) .
- GSE genetic suppressor element
- bcl-2-expressing construct was used to prevent radiation-induced p53 -dependent apoptosis in C8 cells that may affect the properties of conditioned media.
- All the above cells were gamma irradiated (10 Gy) to induce p53 in response to DNA damage, and conditioned media was collected 8 hours after irradiation and compared with that from control non-irradiated cells in a growth inhibitory assay.
- p53 was also activated with tetracycline deprivation.
- KB8-5-11 cells were plated (1000 cells per plate) on sparse monolayers of either p53 -deficient human fibroblasts (MDHA041) or their derivatives expressing wild type p53 (TR9- 7) .
- MDHA041 p53 -deficient human fibroblasts
- TR9- 7 wild type p53
- thrombospondin and IGFBP3 both are encoded by the genes that are upregulated by p53 (Buckbinder et al . , 1995; Dameron et al . , 1994) .
- New candidate secreted growth inhibitors can be found among other p53 -responsive genes found by different methods of identification of the genes whose expression depends on p53 status.
- ⁇ 17- therapy can inhibit growth of tumor cells indirectly by induction of p53 -dependent secretion of growth inhibitory factors by normal cells .
- Such factors can be found among p53 transactivators in culture media and presumably, in blood or other fluids contacting with p53-wt cells in the organism after anti-cancer treatment p53 -dependent secretion of growth inhibitory factors in response to stress is likely to explain the mechanism of tumor bed effect of local gamma radiation on proliferation of non- irradiated tissues.
- These factors could be involved in control of aging since senescent cells accumulated in aging tissues are known to activate p53- dependent gene expression serving as a source of growth inhibitors affecting proliferation and regeneration of tissues .
- the materials and methods used in the experiments in this example are presented below along with a detailed discussion of the results obtained.
- Mouse embryo fibroblasts transformed with Ela+ras from p53-wild type (line C8) and p53-null (line A4) fibroblasts were kindly provided by (Lowe et al . , 1993a) .
- the derivatives of ConA and C8 cells overexpressing bcl-2 or GSE-56 were obtained by retrovirus transduction of the above cDNAs (Nikiforov et al . , 1997) .
- Mouse breast epithelial cell line NMuMG and normal diploid skin fibroblasts were obtained from ATCC. All cell lines were cultivated in DMEM with 10% fetal calf serum. TR9-7 cells were maintained continuously in the presence of 1 ⁇ g/ml of tetracycline; to induce p53 expression, cells were incubated
- PC3 , DU145 and LNCAP were previously described (Rokhlin et al . , 1997).
- Short-term cultures of splenocytes and thymocytes (2-3xl0 7 cells/ml) were prepared from freshly isolated and gently desegrated mouse spleens and thymus glands in RPMI media supplemented with 10% fetal calf serum.
- mice Animals p53 -knockout and control mice (both C57BL) were purchased from Jackson labs, Bar Harbor, Maine.
- cDNA array hybridization Differential hybridization analysis was done with CLONTECH ATLAS cDNA arrays (MacCallum et al . , 1996) and with cDNA microarrays provided by QBI Enterprises, Ltd.
- the ATLAS array consists of 588 selected cDNAs on nylon membrane (MacCallum et al . , 1996) .
- QBI arrays were prepared according to previously described technology (Schena et al . , 1995; website www. clontech . com) by Synteni and contain approximately 20,000 cDNAs .
- Poly (A) + RNA was purified according to standard protocols from different mouse tissues and human cell lines.
- cDNA probe preparation and hybridization was done according to published protocols and manufacturer's recommendations (MacCallum et al . , 1996; website www.clontech.com) .
- Cell proliferation rate was estimated using 3 H-thymidine incorporation as previously describer (Rokhlin et al . , 1997). The experiments were repeated three times using four parallel wells for each tested sample. Conditioned media from gamma- irradiated and control cells and urine from irradiated and control mice were collected 8 hours after irradiation, diluted at different proportions with fresh media (5-50% for conditioned media and 0.1-1% for urine) and loaded on target cells for 48 hours. 3 H-thymidine was added for the last 16 hours of incubation.
- mice 10 athymic nude mice were injected subcutaneously with the suspension of DU145 cells (0.1 ml of growth medium with 5xl0 5 cells per site, 4 sites per mouse) . 5 mice were left untreated while 5 mice were injected intravenously once a day for 6 days with 0.15 ml of nondiluted conditioned media prepared as described above . Mice were examined weekly for tumor growth; the appearance of tumors detectable by palpation is indicated in Figure 1.
- DNA and mRNA sequences were retrieved from GENBANK Database and searched for p53 binding sites within the range of +2 kb relative to the trascription start point.
- One of two additional mismatches and 1-7 bp gaps between half-sites were allowed.
- Weakened consensus RVNCHWGYYBNi- a RVCWHGYYB was used to allow for naturally occurring mutations in known p53 binding sites. Resulting sequences were accepted if they had no more than 3-4 mismatches in total from the previously defined consensus RRRCWWGYYYN 0 . 13 RRRCWWGYYY (El-Deiry et al . , 1992) and no more than 1 mismatch was allowed inside CWWG core sequences per half-site dimer.
- p53-responsive genes that alter their expression in response to gamma irradiation in a series of cell systems (source of RNA for hybridization) differing in their origin and p53 status were determined.
- p53-negative fibroblasts MDAH041 and its derivative, TR9-7 which express tetracycline-regulated wild type p53 cDNA
- Alpha 1-proteinase inhibitor 2 X66454(R) + UD Nl** -1 153; +1489
- Macrophage CSF-1 receptor (CSF-1) 1163963(H) Nl Nl + >+862; >+1540
- Hyaluronan synthase 2 (HAS2) U54804 - >+1596**
- the genes identified include a number of known p53 responders (Tables 1 and 2) : p21/wafl , cyclin G, bax and several genes encoding enzymes of glutathione metabolism. Only one gene, cyclin G (Okamoto et al . , 1994), among those tested, was recognized as a p53 responder in all mouse tissues analyzed. p53 -dependent upregulation of p2 l/ wafl and bax was evident in some of the cell types tested but was undetectable in others, possibly due to low basal expression levels. Transcription of the E124 gene (Lehar et al . , 1996), was activated by gamma irradiation in all mouse organs tested, but in the liver, this activation was p53 independent.
- the largest group of p53 responders includes genes that are upregulated after gamma irradiation on p53 wild type but not on p53-null background (p2l/wafl , cyclin G, TGF- ⁇ 2, etc) .
- Another large group involves genes which basal expression levels was higher in p53-null cells than in p53 wild type cells. They were upregulated in p53 wild type cells and, in some cases, in p53-null cells after gamma irradiation (ne roleukin, ID-1 , ID-3 , see Figs. 3A and 3B) .
- Another group of genes are subjects of complex regulation (Figs. 2A and 2B) .
- cyclin Bl that is downregulated after gamma irradiation through the known mechanism involving mRNA degradation (Maity et al . , 1995) was upregulated by p53 induced in TR9-7 cells by tetracyclin deprivation (Figs. 3A and 3B) .
- thymus and spleen which both are highly sensitive to p53 -dependent apoptosis, exhibit almost non-overlapping sets of p53- dependent gene expression (Table 1) .
- the tissue specificity of p53 responsiveness of some of the identified genes seems to simply reflect the differences in the basal levels of their expression among tissues. For example, p53-induced upregulation of pl9/ink4/arf was evident in the spleen, where its basal level is low, and could not be detected in the thymus where its expression was high. p!9/ink4/arf expression in the liver was below the sensitivity of hybridization.
- tissue specific response to p53 suggesting that p53 pathway can be modulated by unknown tissue specific factors.
- tissue specificity of the majority of p53 responders suggests that some unknown factors target p53 to different groups of promoters.
- Newly identified p53 responders can be organized into several groups according to their responses to p53 and their functional activities.
- One of the major subgroups includes several genes encoding enzymes of glutathione metabolism, reflecting the recent discovery of p53 involvement in the regulation of reactive oxygen (Hermeking et al . , 1997) .
- transcription regulators activating transcription factor 4, c-Jun protooncogene, p45 NF-E2 related factor 2 and ID-1, ID-2
- growth factors and their receptors nerve growth factor alpha; neuroleukin; EGF; granulocyte- macrophage CSR receptor; macrophage CSF-1 receptor (CSF-1)
- extracellular matrix proteins collagen ⁇ l type IX; collagen ⁇ l type IV; collagen ⁇ l type XIV; collagen ⁇ l type I; collagen ⁇ 2 typel.
- basal levels of neuroleukin and cathepsin H mRNAs were significantly decreased in p53 wild type cells and were upregulated after gamma irradiation in p53 -independent manner.
- Expression of serine proteinase inhibitor 2 is induced by radiation in both p53 wild type and p53-null splenocytes, but induction was significantly stronger with p53 (Table 1, Fig.2A) .
- Some genes that were upregulated in p53 -dependent manner after gamma irradiation in spleen, liver, and fibroblasts encode secreted proteins with a known growth inhibitory function.
- Different secreted inhibitors were activated in different cell types. They include TGF- ⁇ 2, inhibin- ⁇ (in fibroblasts) , and a variety of serine protease inhibitors ( spleen, liver and fibroblasts ; alpha 1 - proteinase inhibitor 2; serine proteinase inhibitor 2; serine proteinase inhibitor 2,4 and glia derived nexin-1; antileukoproteinase 1; thrombospondin 2) .
- Insulin-like growth factor-binding protein 3 defined earlier as a p53 responder (Buckbinder et al . , 1995) also belongs to this group, although its p53 -dependent upregulation was visible only in human fibroblasts.
- the presence of a large number of secreted inhibitors among p53 -responsive genes suggests that p53 -dependent growth control may not be limited only to suppression of damaged cell proliferation by internal mechanisms, but may also involve induction and release of growth inhibitory factors affecting the surrounding cells (bystander effect) .
- the effect of conditioned media from cells differing in their p53 status before and after p53 activation was compared.
- p53-null human fibroblasts MDAH041 were compared with their derivatives TR9- 7, expressing tetracycline-regulated p53 (Agarwal et al . , 1995);
- ConA cells (Komarova et al., 1997) were compared with their variant in which p53 function was suppressed by transduction of a strong anti-p53 genetic suppressor element GSE-56 (Ossovskaya et al .
- tetracycline deprivation was used to activate p53 in TR9-7 cells.
- Several cell types were used as targets in growth- inhibition assays. They include three prostate carcinoma cell lines, PC3 , DU145, and LNCAP and three nearly normal cells: human and mouse diploid fibroblasts and nontransformed murine mammary gland epithelial cells NmuMG. Similar results were obtained with all cell lines, and we chose DU145 cells as reference target cells for further analysis because they are known to be the most resistant to conventional anticancer treatments among the tested cell lines (Rokhlin et al . , 1997) .
- DU145 cells were chosen for the demonstration of the effect since they are resistant to many known negative regulatory stimuli, including TGF- ⁇ , TNF- ⁇ , interferon- ⁇ and FAS ligand; these cells are p53 -deficient and do not undergo apoptosis in response to treatment with radiation or DNA-damaging chemo therapeutic drugs (Rokhlin et al . , 1997) .
- Conditioned medium from untreated p53 wild type cells did not affect the growth of
- Figs. 5A and 5B demonstrate the growth-suppressive effect detected both ex vivo in conditioned media from splenocytes and in vivo in urine of irradiated animals. In both cases, the effect was p53 -dependent (Figs. 5A and 5B) .
- Conditioned media from short-term cultures of irradiated thymocytes did not display any detectable growth suppressive activity (data not shown) ; consistently, no secreted proteins were found among the products of a few p53 -responsive genes of thymus (see Table 1) .
- the conditioned media from irradiated splenocytes induced apoptosis in target tumor cells (Fig. 1) .
- the growth suppressive effects of conditioned medium and urine were more pronounced in the three tumor cell lines tested than in three types of normal cells, including mouse and human diploid fibroblasts and mouse mammary gland epithelial cells NmuMG (Fig. 5C) .
- chemo- and radiation therapy raises the possibility that chemo- and radiation therapy may act not only by causing direct damage to tumor cells, but also by inducing "export" of anti-proliferative stimuli and the release of growth inhibitors by normal cells in response to stress, thereby affecting growth of their neighbors.
- chemotherapeutic drug on drug-resistant tumor cells, co-cultivated with nonmalignant fibroblasts, either p53 -deficient fibroblasts (MDAH041) or with their derivatives expressing wild type p53 (TR9-7) , was compared.
- the multidrug- resistant tumor cell line KB8-5-11 which is resistant to adriamycin due to the overexpression of P-glycoprotein (P-gp) (Roninson et al . , 1986), was used.
- KB8-5-11 cells were plated
- the p53 -dependent secretion of growth inhibitors with potential anticancer activity detected both in conditioned medium and in body fluids indicates a novel growth regulatory function of p53 : stress-dependent cellular export of growth inhibitory stimuli. This function possibly determines the "bystander effect" associated with p53 gene therapy (Qazilbash et al . , 1997) .
- HAS2 hyaluronan synthase 2
- HAS2 hyaluronan synthase 2
- DU145 and PC3 cells are p53-deficient , while the rest of the target cells tested have wild type p53.
- Some of the p53 -dependent factors have profound anticancer activity and are already used as supplements to chemotherapeutic treatments. These include members of the TGF- ⁇ family and numerous serine protease inhibitors and their chemical functional analogs, which are emerging as potential tools to treat cancer (DeClerck et al . , 1994).
- the p53 -dependent modulation of gene expression in gamma-irradiated fibroblasts clearly reflects morphological and physiological alterations in irradiated tissues associated with growth attenuation of tumors transplanted in gamma irradiated organs (O'Brien et al., 1969) known as the tumor bed effort (TBE) .
- TBE tumor bed effort
- induction of various collagen species and suppression of collagen-degrading proteinases correlates with deposition of collagen by connective tissue in coarse bundles following irradiation.
- Morphological and physiological alterations of normal tissues associated with aging may well be another phenomenon related to the newly determined function of p53.
- Senescent cells that accumulate in tissues over time are known to maintain very high levels of p53-dependent transcription (Atadja et al., 1995).
- p53-dependent secretion of growth inhibitors by senescent cells, accumulating in aging tissue may affect proliferating cells and lead to a gradual decrease in overall proliferation capacity of tissues associated with age. Identification of p53 -dependent growth inhibitors allows this hypothesis to be tested directly.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL13793999A IL137939A0 (en) | 1998-02-23 | 1999-02-23 | P53-dependent secretion of growth inhibitory factors |
AU27794/99A AU2779499A (en) | 1998-02-23 | 1999-02-23 | P53-dependent secretion of growth inhibitory factors |
CA002321132A CA2321132A1 (en) | 1998-02-23 | 1999-02-23 | P53-dependent secretion of growth inhibitory factors |
JP2000532012A JP2002503488A (en) | 1998-02-23 | 1999-02-23 | P53-dependent secretion of growth inhibitors |
EP99908335A EP1063887A1 (en) | 1998-02-23 | 1999-02-23 | P53-dependent secretion of growth inhibitory factors |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7549098P | 1998-02-23 | 1998-02-23 | |
US8475598P | 1998-05-08 | 1998-05-08 | |
US60/084,755 | 1998-05-08 | ||
US60/075,490 | 1998-05-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999041985A1 true WO1999041985A1 (en) | 1999-08-26 |
Family
ID=26756924
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/003777 WO1999041985A1 (en) | 1998-02-23 | 1999-02-23 | P53-dependent secretion of growth inhibitory factors |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1063887A1 (en) |
JP (1) | JP2002503488A (en) |
AU (1) | AU2779499A (en) |
CA (1) | CA2321132A1 (en) |
IL (1) | IL137939A0 (en) |
WO (1) | WO1999041985A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003043565A2 (en) * | 2001-09-24 | 2003-05-30 | University Of Aarhus | Methods for diagnosis and treatment of diseases associated with altered expression of nrf2 |
US6696441B1 (en) | 2000-08-11 | 2004-02-24 | The Regents Of The University Of California | Inhibition of p53-induced stress response |
US7601846B2 (en) | 2001-06-26 | 2009-10-13 | The Regents Of The University Of California | Compounds having activity as inhibitors of apoptosis |
-
1999
- 1999-02-23 IL IL13793999A patent/IL137939A0/en unknown
- 1999-02-23 JP JP2000532012A patent/JP2002503488A/en active Pending
- 1999-02-23 WO PCT/US1999/003777 patent/WO1999041985A1/en not_active Application Discontinuation
- 1999-02-23 EP EP99908335A patent/EP1063887A1/en not_active Withdrawn
- 1999-02-23 CA CA002321132A patent/CA2321132A1/en not_active Abandoned
- 1999-02-23 AU AU27794/99A patent/AU2779499A/en not_active Abandoned
Non-Patent Citations (3)
Title |
---|
DATABASE CAPLUS ON STN, BALE et al., "Regulation of Insulin-Like Growth Factor Binding Protein-3 Messenger Ribonucleic Acid Expression by Insulin-Like Growth Factor I"; & ENDOCRINOLOGY, 1992, Vol. 131, No. 2, pages 608-614. * |
DATABASE EMBASE ON STN, KOMAROVA et al., "Stress-Induced Secretion of Growth Inhibitors: A Novel Tumor Suppressor Function of p53"; & ONCOGENE, 03 September 1998, Vol. 17, No. 9, pages 1089-1096. * |
DATABASE SCISEARCH ON STN, TANG et al., "Expression of Transforming Growth-Factor-beta(TGF-BETA)Isoforms and TGF-beta Type II Receptor Messenger-Ribonucleic-Acid and Protein and the Effect of TGF-beta-S on Endometrial Stromal Cell-Growth and Protein Degradation In-Vitro"; & ENDOCRINOLOGY, July 1994, Vol. * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6696441B1 (en) | 2000-08-11 | 2004-02-24 | The Regents Of The University Of California | Inhibition of p53-induced stress response |
US7601846B2 (en) | 2001-06-26 | 2009-10-13 | The Regents Of The University Of California | Compounds having activity as inhibitors of apoptosis |
WO2003043565A2 (en) * | 2001-09-24 | 2003-05-30 | University Of Aarhus | Methods for diagnosis and treatment of diseases associated with altered expression of nrf2 |
WO2003043565A3 (en) * | 2001-09-24 | 2003-11-13 | Univ Aarhus | Methods for diagnosis and treatment of diseases associated with altered expression of nrf2 |
Also Published As
Publication number | Publication date |
---|---|
AU2779499A (en) | 1999-09-06 |
CA2321132A1 (en) | 1999-08-26 |
IL137939A0 (en) | 2001-10-31 |
JP2002503488A (en) | 2002-02-05 |
EP1063887A1 (en) | 2001-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Komarova et al. | Stress-induced secretion of growth inhibitors: a novel tumor suppressor function of p53 | |
Párrizas et al. | Insulin-like growth factor-1 inhibition of apoptosis is associated with increased expression of the bcl-xL gene product | |
Leinninger et al. | Phosphatidylinositol 3‐kinase and Akt effectors mediate insulin‐like growth factor‐I neuroprotection in dorsal root ganglia neurons | |
Xu et al. | Extracellular progranulin protects cortical neurons from toxic insults by activating survival signaling | |
Sukhai et al. | Decreased expression of P-glycoprotein in interleukin-1β and interleukin-6 treated rat hepatocytes | |
DE69535462T2 (en) | Composition and method for inhibiting filament formation of the amyloid betaprotein and its neutotoxicity | |
DE69914463T2 (en) | THERAPEUTIC CHEMOKINE RECEPTOR ANTAGONISTS | |
Kim et al. | Regulation of replicative senescence by insulin‐like growth factor‐binding protein 3 in human umbilical vein endothelial cells | |
Cassel et al. | Mitogenicity of brain axolemma membranes and soluble factors for dorsal root ganglion Schwann cells | |
US6150345A (en) | Methods for promoting survival of myelin producing cells | |
Bek et al. | Expression and function of C/EBP homology protein (GADD153) in podocytes | |
Pertile et al. | Reovirus infection in chickens primes splenic adherent macrophages to produce nitric oxide in response to T cell-produced factors | |
EP0731697B1 (en) | Ssi tyrphostins and pharmaceutical compositions | |
Ruutu et al. | Defective neutrophil migration in monosomy-7 | |
Taniwaki et al. | Ceramide induces apoptosis to immature cerebellar granule cells in culture | |
Zhang et al. | Higenamine promotes M2 macrophage activation and reduces Hmgb1 production through HO-1 induction in a murine model of spinal cord injury | |
Yang et al. | Human RPE expression of cell survival factors | |
Rampalli et al. | Insulin regulates expression of c-fos and c-jun and suppresses apoptosis of lens epithelial cells | |
Evans et al. | Apoptosis: cellular signaling and molecular mechanisms | |
KR20100121710A (en) | Method for prevention and treatment of retinal degeneration comprising activity regulation and administration of pten | |
WO2022032703A1 (en) | Application of histone deubiquitinase in preparation of drugs for preventing aging and treating aging-related diseases | |
WO2009103493A1 (en) | Sgk1 as a therapeutic and diagnostic target for viral diseases | |
EP1063887A1 (en) | P53-dependent secretion of growth inhibitory factors | |
de Lima et al. | Evaluation of the mutagenic activity of hydroxyurea on the G1-S-G2 phases of the cell cycle: an in vitro study | |
KR100742737B1 (en) | Composition containing eupatilin as a effective ingredient with a usage as prevention of disease mediated with gap junction damage |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2321132 Country of ref document: CA Ref country code: CA Ref document number: 2321132 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 137939 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 27794/99 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 532012 Kind code of ref document: A Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999908335 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1999908335 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999908335 Country of ref document: EP |